

**REMARKS**

Claims 1-18 and 20-42, 45 and 46 are presented. Claim 44 together with further dependent claims have been allowed in parent application Serial No. 09/144,096 filed August 31, 1998, of which the present application is a continuation application.


Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "**Version With Markings To Show Changes Made.**"

Action on the present application is awaited.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

0933436 042001

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

1 (Amended). A method for treating or preventing pathophysiological consequences of mitochondrial respiratory chain dysfunction in a mammal comprising administering to said mammal in need of such treatment or prevention an effective amount of a pyrimidine nucleotide precursor, thereby treating or preventing said consequences; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

32 (Amended). A method for preventing death or functional decline of post-mitotic cells in a mammal due to mitochondrial respiratory chain dysfunction comprising administration of an effective amount of a pyrimidine nucleotide precursor, thereby preventing said death or functional decline; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

36 (Amended). A method for treating developmental delay in cognitive, motor, language, executive function, or social skills in a mammal comprising administration of an effective amount of a pyrimidine nucleotide precursor, thereby treating said developmental delay; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.

41 (Amended). A method for reducing side effects of cytotoxic cancer chemotherapy agents by administering a pyrimidine nucleotide precursor, where said cytotoxic chemotherapy agent is not a pyrimidine nucleoside analog, thereby reducing said side-effects; wherein said effective amount is from 0.05 to 0.3 grams of said precursor per kilogram body weight per day.